Omavelexolone’s Potential in Friedreich Ataxia: David R. Lynch, MD, PhD
September 24th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]
Ongoing Therapeutic Developments for Movement Disorders: Saar Anis, MD
September 23rd 2021When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
Understanding the Use of Medical Cannabis for Movement Disorders: Saar Anis, MD
September 22nd 2021Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]
Future Direction of AI, Neuroimaging Research: Michael Dwyer, PhD
September 22nd 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]
Studying Effects of Gender and Sex in Alzheimer Disease: Jessica Caldwell, PhD
September 21st 2021The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.
EvoWalk Digital Therapy Platform Pilot Program Launched by Evolution Devices
September 21st 2021Lisa Donahue PT, MPT, NCS, the director of Clinical Services at Evolution Devices, offered details about the EvoWalk platform, its potential in neurorehabilitation efforts, and its future clinical availability.
Omaveloxolone Continues to Demonstrate Positive Effect on Friedrich Ataxia
September 19th 2021Patients previously randomized to omaveloxolone in the core study period continued to show no worsening on modified Friedrich Ataxia Rating Scale relative to their original baseline after nearly 2.5 years of treatment.